<乌鸦传媒>Novel Turmeric Derivative Drug Shows Promise in Head and Neck Cancer Compound is still in earliest stages of testing Jul 10, 2023
<乌鸦传媒>Oral Cancer Patients Face Worse Outcomes With Delayed Radiation Therapy Failure to initiate adjuvant radiation therapy within 6 weeks tied to survival rates Jul 10, 2023
<乌鸦传媒>Liquid Biopsy May Help Identify HPV-Associated Oropharyngeal Cancer But concerns about false negative results linger Jul 10, 2023
<乌鸦传媒>Primary Surgery vs Radiation in Oropharyngeal Cancer: Does One Come Out a Winner? Higher short-term dysphagia risk with surgery, but RT/CRT had worse 5-year OS Jul 09, 2023
<乌鸦传媒>IMRT Dosing Strategy Eases Dysphagia in Head and Neck Cancer A new standard for patients receiving intensity-modulated radiotherapy for pharyngeal cancers? Jul 07, 2023
<乌鸦传媒>Wisconsin Ob/Gyn Surrenders Medical License After Patient's Death Victoria Mondloch, MD, was previously disciplined for providing substandard medical care Jul 07, 2023
<乌鸦传媒>Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL 73% of patients with prior exposure to covalent BTK inhibitors responded Jul 05, 2023
<乌鸦传媒>EphrinB2 Expression in Urothelial Cancer Tied to Checkpoint Inhibitor Activity Retrospective data confirm EphrinB2 as a negative prognostic marker Jul 05, 2023 video
<乌鸦传媒>I Can't Guarantee Your Next Round of Chemo Physicians face difficult conversations and decisions amid chemo drug shortages Jul 05, 2023
<乌鸦传媒>FDA Gives Nod to Gene Therapy for Hemophilia A First gene therapy approved for severe hemophilia A Jun 29, 2023
<乌鸦传媒>WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancer News, features, and commentary about cancer-related issues Jun 29, 2023
<乌鸦传媒>TXA Holds Its Own for Heavy Menstrual Bleeding in von Willebrand Disease In phase III study, recombinant VWF not superior to cheaper alternative for type 1 and 2 cases Jun 29, 2023
<乌鸦传媒>Continuing Trastuzumab After Progression Shows Promise in HER2+ Gastric/GEJ Cancer Adding anti-HER2 agent to ramucirumab, paclitaxel exceeds historical PFS with doublet Jun 28, 2023
<乌鸦传媒>No OS Benefit With Ibrutinib in Early-Stage, High-Risk CLL Study suggests "watch and wait" should remain standard of care Jun 28, 2023
<乌鸦传媒>Agent Orange Exposure Tied to Bladder Cancer Risk in Veterans Increased risk described as "modest," and no association seen with aggressiveness of cancer Jun 27, 2023
<乌鸦传媒>PET-CT Superior to Conventional Scans for Spotting Distant Breast Cancer Mets Study shows twice as many locally advanced patients upstaged with PET-CT vs conventional staging Jun 26, 2023
<乌鸦传媒>Can AI Help Determine if Liver Cancer Will Respond to Standard Treatment? Early model suggests a way to predict progression-free survival Jun 26, 2023
<乌鸦传媒>Why Did Older Man Develop Itchy, Full-Body Rash? Here's how the medical team diagnosed and treated the rare inflammatory skin disorder Jun 22, 2023
<乌鸦传媒>Rates of Consent Withdrawal in Cancer Trials Low but Not 'Trivial' Factors associated with greater likelihood of withdrawal included Hispanic ethnicity, older age Jun 22, 2023
<乌鸦传媒>Breast Cancer Recurrence Risk Varies by Molecular Subtype Korean study suggests need for individualized surveillance, optimized use of breast MRI Jun 21, 2023
<乌鸦传媒>Earlier Detection of Cardiac Dysfunction Possible for Young Adult Cancer Survivors A case for monitoring global longitudinal strain despite normal LVEF Jun 20, 2023
<乌鸦传媒>Daily Low-Dose Aspirin Upped Incidence of Anemia in Older Adults An analysis of the ASPREE trial showed 100-mg aspirin led to more anemia events vs placebo Jun 19, 2023
<乌鸦传媒>Breast Cancer Drugs May Weaken Effects of Weight-Loss Drugs Survivors on aromatase inhibitors lost significantly less weight Jun 18, 2023
<乌鸦传媒>New Bispecific Antibody Approved for Tough-to-Treat Lymphoma Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate Jun 16, 2023
<乌鸦传媒>Cystic Renal Masses Often Harbor High-Grade Disease No link between grade and cancer-specific survival, active surveillance still an option for many Jun 16, 2023
<乌鸦传媒>Early Invasive Breast Cancer Now Leaves Mostly Long-Term Survivors Mortality risk has decreased substantially since the 1990s Jun 15, 2023
<乌鸦传媒>Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortages News, features, and commentary about cancer-related issues Jun 15, 2023
<乌鸦传媒>Base-Edited CAR-T Product 'Potent' in Relapsed Childhood T-Cell ALL One young patient achieved molecular remission within 28 days of infusion Jun 14, 2023
<乌鸦传媒>Pre-Existing Depression, Anxiety Tied to Worse DLBCL Prognosis Patients with depression alone had the worst overall survival Jun 13, 2023
<乌鸦传媒>CRISPR Therapy Exceeds Targets in Thalassemia, Sickle Cell Disease Results "indicate that exa-cel can provide a one-time functional cure," says researcher Jun 13, 2023
<乌鸦传媒>Breast Ultrasound Recs May Not Be Targeting the Right Women It's not just dense breasts that matter, researchers say Jun 12, 2023
<乌鸦传媒>CAR-T for Chronic Lymphocytic Leukemia Hits Goal of Mid-Stage Trial All patients had progressed on BTK inhibitors and most had failed venetoclax Jun 12, 2023
<乌鸦传媒>Hooray! A Clearer Estimate of Your Risk for Death Is Here Researchers do the legwork to incorporate smoking status into NCI's "Know Your Chances" website Jun 09, 2023
<乌鸦传媒>TTFields Therapy Yields OS Improvement in Second-Line NSCLC However, device was not tested alongside current standard of care, expert points out Jun 08, 2023
<乌鸦传媒>How Vax Skeptics Sow Doubt; Gun Death Every 11 Minutes; 90210 Star's Cancer Spreads Health news and commentary from around the Web gathered by 乌鸦传媒 staff Jun 08, 2023
<乌鸦传媒>Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer No PFS, OS benefit with first-line versus second-line CDK4/6 inhibition, more toxicity, cost Jun 07, 2023
<乌鸦传媒>Skipping Radiotherapy 'Seems Safe' for PMBCL Patients in Remission PET-negative patients after chemoimmunotherapy fared well with observation alone Jun 07, 2023
<乌鸦传媒>FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer Survival benefit supports FGFR testing for all patients with metastatic disease, researcher says Jun 07, 2023
<乌鸦传媒>Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLC "Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert Jun 07, 2023
<乌鸦传媒>Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Years Retrospective study finds no difference in OS between patients who stop and those who continue Jun 06, 2023
